Cargando…
Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +/− oral antifungal therapy. Despite this, many patients continue to have severe symptoms, and...
Autores principales: | Ali, Muhammad, Green, O’Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081018/ https://www.ncbi.nlm.nih.gov/pubmed/33948179 http://dx.doi.org/10.1093/omcr/omaa029 |
Ejemplares similares
-
Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab
por: Mikura, Sunao, et al.
Publicado: (2021) -
Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report
por: Nishimura, Tadashi, et al.
Publicado: (2021) -
A Case of Allergic Bronchopulmonary Aspergillosis With Failure of Benralizumab and Response to Dupilumab
por: Kotetsu, Yasuaki, et al.
Publicado: (2023) -
Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report
por: Kai, Yoshiro, et al.
Publicado: (2022) -
Tezepelumab treatment for allergic bronchopulmonary aspergillosis
por: Ogata, Hiroaki, et al.
Publicado: (2023)